Genome-wide CRISPR-Cas9 screen identifies sensitizers to LSD1 inhibition in MLL-translocated human AML cells
Affiliation
Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Manchester,Issue Date
2018
Metadata
Show full item recordCitation
Deb G, Wingelhofer B, Williams E, Leong H-S, Somervaille TCP. Genome-wide CRISPR-Cas9 screen identifies sensitizers to LSD1 inhibition in MLL-translocated human AML cells. Blood. 2018;132.Journal
BloodDOI
10.1182/blood-2018-178Additional Links
https://dx.doi.org/10.1182/blood-2018-178Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2018-178